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Objectives. In this study we quantified the effects of a critical
coronary stenosis on global systolic function using pressure-
volume relations at baseline and during incremental dobutamine
stress.
Background. The effects of coronary stenosis have previously
been analyzed mainly in terms of regional (dys)function. Global
hemodynamics are generally considered normal until coronary
flow is substantially reduced. However, pressure-volume analysis
might reveal mechanisms not fully exposed by potentially load-
dependent single-beat parameters. Moreover, no systematic anal-
ysis by pressure-volume relations of the effects of dobutamine over
a wide dose range has previously been presented.
Methods. In 14 dogs left ventricular volume and pressure were
measured by conductance and micromanometer catheters, and
left circumflex coronary flow by Doppler probes. Measurements in
control and with left circumflex stenosis were performed at
baseline and at five levels of dobutamine (2.5 to 20 mg/kg/min).
The end-systolic pressure-volume relation (ESPVR) dP/dtMAX 2
vs. end-diastolic volume (dP/dtMAX 2 VED) and the relation
between stroke work and end-diastolic volume (preload re-
cruitable stroke work [PRSW]) were derived from data obtained
during gradual caval occlusion.
Results. In control, dobutamine gradually increased heart rate
up to 20 mg/kg/min, the inotropic effect blunted at 15 mg/kg/min.
With stenosis, the chronotropic effect was similar, however, con-
tractile state was optimal at approximately 10 mg/kg/min and
tended to go down at higher levels. At baseline, the positions of
ESPVR and PRSW, but not of dP/dtMAX 2 VED, showed a
significant decrease in function with stenosis. No differences
between control and stenosis were present at 2.5 mg/kg/min; the
differences were largest at 15 mg/kg/min.
Conclusions. Pressure-volume relations and incremental do-
butamine may be used to quantify the effects of critical coronary
stenosis. The positions of these relations are more consistent and
more useful indices than the slopes. The positions of the ESPVR
and PRSW show a reduced systolic function at baseline, normal-
ization at 2.5 mg/kg/min and a consistent significant difference
between control and stenosis at dobutamine levels of 5 mg/kg/min
and higher.
(J Am Coll Cardiol 1998;32:816–26)
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Coronary occlusion leads to a rapid loss of function with
reduced shortening in the ischemic zone within a few cardiac
cycles and systolic elongation within 30 s (1). These effects on
both regional and global function have been studied exten-
sively. Although clinically highly relevant, few data are avail-
able concerning the effects of coronary stenosis, especially in
terms of global systolic function. Previous studies involving
coronary stenoses have mainly focused on the regional effects
(2–9). In addition, although stress testing is a common method
to reveal the physiologic significance of a stenosis, no system-
atic analysis of global systolic function by pressure-volume
relations with incremental stress levels has previously been
presented. Most studies indicate that baseline global hemody-
namics are normal in the presence of a stenosis up to the level
where regional coronary flow is substantially reduced (10–12).
We felt, however, that careful analysis of systolic function by
means of pressure-volume relations could reveal the presence
of the stenosis even at rest. In addition, we hypothesized that
the heterogeneity induced by the stenosis might lead to a
biphasic response of global function upon dobutamine stimu-
lation, typically showing relatively improved function at low
dobutamine levels when the normal region is able to compen-
sate for the region supplied by the stenotic artery, and deteri-
oration at higher levels of dobutamine stimulation. Recently, a
similar “biphasic” response has been shown at a regional level
and it was shown that the detection of myocardial ischemia by
stress dobutamine echocardiography may be significantly en-
hanced by using this concept (13,14).
Therefore, our goal was to assess the effects of a critical
coronary stenosis on global systolic ventricular function at
baseline and during a wide range of stress levels induced by
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dobutamine infusion. Ventricular function was quantified by
parameters derived from systolic pressure-volume relations,
and their relative sensitivity to detect changes in function
induced by the stenosis, dobutamine stimulation and the
combined effect of these interventions, was investigated.
Methods
Animals. Studies were performed in 14 beagles, weighing
12.5 to 16.4 kg. The protocol was approved by the animal
research committee of the University of Leiden.
Surgery and instrumentation. After sedation with 5 to
10 ml of Hypnorm (10 mg/ml fluanison and 0.2 mg/ml fentanyl
IM) and intubation, anesthesia was initiated with 3 ml fentanyl
citrate (0.05 mg/ml) and 1 ml lorazepam (Temesta, 4 mg/ml).
General anesthesia was maintained with continuous IV infu-
sion of fentanyl citrate (Fentanyl, 0.05 mg/kg/h) and sodium
pentobarbitone (Nembutal, 7.5 mg/kg/h). Pancuronium bro-
mide (Pavulon, 1 to 2 mg/h IV) was used as a muscle relaxant.
The dogs were ventilated with room air and oxygen. Arterial
blood gases were repeatedly measured and ventilation was
adjusted as required to maintain normal arterial oxygen and
carbon dioxide pressures throughout the study. Dextran and
saline were infused as needed to maintain stable conditions,
occasionally supplemented by sodium bicarbonate to adjust the
base deficit. To facilitate catheter insertion 7F sheaths were
placed in both the left and right femoral arteries and veins.
Additional sheaths were placed in the left carotid artery and
left jugular vein and a bilateral vagotomy was performed. A left
lateral thoracotomy was performed at the fifth intercostal
space and the pericardium was opened. The proximal left
circumflex coronary artery was dissected free and instrumented
with a Doppler velocity probe (Crystal Biotech, Holliston,
MA). The probe was connected to a 20 MHz, range-gated,
pulsed Doppler velocitymeter (VF-1, Crystal Biotech). Ap-
proximately 5 mm distal to the probe a silk suture was put
around the left circumflex coronary artery and both ends of the
suture were passed through a length of tygon tubing to create
an adjustable stenosis. A 7F, 12-electrode dual-field conduc-
tance catheter (Webster Laboratories, Baldwin Park, CA) with
7-mm interelectrode spacing was positioned along the long axis
of the left ventricle. The conductance catheter was connected
to a Leycom Sigma-5 DF signal processor (CardioDynamics,
Zoetermeer, the Netherlands) to measure instantaneous left
ventricular volume (15,16). A 5F angiographic catheter was
advanced to the main pulmonary artery for determination of
the parallel conductance calibration factor using the hyper-
tonic saline dilution method. A 7F micro manometer pressure
catheter (Dra¨ger Medical Electronics, Best, the Netherlands)
was positioned in the left ventricle. A 5F atrioseptostomy
balloon catheter was advanced in a femoral vein and posi-
tioned in the inferior vena cava just below the right atrium. The
balloon catheter served to occlude the inferior vena cava and
reduce preload. All catheters were placed under fluoroscopic
guidance. Lead II electrocardiograms were taken from subcu-
taneous needle electrodes. All analog signals were displayed
on a multi-channel monitor. Left ventricular pressure and
volume signals were also displayed on a X-Y oscilloscope for
continuous monitoring of pressure-volume loops. All signals,
including five segmental volume signals, were connected to a
PC-based data-acquisition system, and during the various
interventions data were digitized with 12-bit accuracy at a
sample rate of 200 Hz and stored on hard disk for subsequent
analysis.
Protocol. Dobutamine was infused at incremental doses: 0
(5 no dobutamine stimulation), 2.5, 5, 10, 15 and 20 mg/kg/
min. At each dose, 5 min were allowed to reach a new steady
state before hemodynamic measurements (see below) were
taken. After these measurements dobutamine infusion was
discontinued and at least 15 min were allowed to return to
baseline conditions. Next, a left circumflex stenosis was created
distal to the velocity probe: guided by the coronary flow
measurement the string occluder was slowly adjusted to reach
a mean flow just below the pre-occlusion value. After a 15-min
stabilization period the dobutamine infusion protocol was
repeated.
Hemodynamic measurements. At each level of dobut-
amine, before and after creating the coronary stenosis, the
following measurements were performed. (To avoid confusion,
measurements in the absence of a stenosis will be referred to
as “control” and measurements without dobutamine stimula-
tion as “baseline.”) To calibrate the conductance method,
blood resistivity was measured and at least two hypertonic
saline injections were performed to determine parallel conduc-
tance. To assess left ventricular function, all hemodynamic
signals were acquired during inflation of the caval balloon to
decrease preload of the heart. This way, a gradual pressure
drop of 4 to 5 kPa could generally be obtained within 10 s.
Since respiration may influence parallel conductance mea-
sured by the conductance catheter as well as the actual
end-diastolic volume, all data were acquired with respiration
suspended at end-inspiration.
Calculations. Left circumflex coronary flow (QLCX). Left
circumflex coronary flow was calculated from the Doppler
velocity measurements (17). Mean QLCX was calculated for
each beat during the loading intervention and plotted vs.
Abbreviations and Acronyms
CO 5 cardiac output
ESPVR 5 end-systolic pressure-volume relation
EES 5 end-systolic elastance
PES 5 end-systolic pressure
PRSW 5 preload recruitable stroke work (relation
between stroke work and end-diastolic volume)
QLCX 5 left circumflex coronary flow
SV 5 stroke volume
SW 5 stroke work
VES 5 end-systolic volume
VED 5 end-diastolic volume
superscriptIND 5 determined at fixed end-diastolic volume (or at
fixed end-systolic pressure for QLCX and VES)
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end-systolic pressure (PES). Next, QLCX was determined at a
fixed PES level (the definition of this pressure level is given
below with the description of the end-systolic pressure-volume
relation). This value, QLCX
IND, was used to compare coronary
flows in the various conditions.
Left ventricular volume. Left ventricular volume was ob-
tained with the conductance catheter method (15). Briefly, a
multielectrode catheter is employed to measure electrical
conductances at five levels in the ventricle. The instantaneous
conductance-signals, G(t), are converted to volume-signals,
VLV(t), as: VLV(t) 5 (1/a).L
2.r.G(t) 2 Vc. Here, a is a
dimensionless slope factor, L the distance between the sensing
electrodes, r the resistivity of blood and Vc the correction
volume for the conductance of surrounding tissue (commonly
referred to as parallel conductance). The correction volume
was determined by the saline dilution method (15). Since we
were mainly interested in within-animal effects, the slope
factor was not assessed and assumed to be 1.
Left ventricular function. Data acquired during caval occlu-
sion were used to derive pressure-volume relations. To this end
we selected a time frame beginning where both systolic pres-
sure and volume started to fall and included all subsequent
beats where pressure and volume continued to fall. Individual
beats were distinguished using the R-wave of the electrocar-
diogram. Systolic function was assessed by considering the
relations below. Both increased slope and leftward or upward
shift of these relations are indicative of increased inotropism.
1. The end-systolic pressure-volume relation (ESPVR) (18).
End-systole was defined as the time point in the cardiac cycle
of maximal elastance. Time-varying elastance is calculated as
E(t) 5 PLV(t)/(VLV(t) 2 V0), where PLV(t) and VLV(t) are
instantaneous left ventricular pressure and volume. The vol-
ume intercept (V0) was calculated by an iterative algorithm
(19,20). The end-systolic pressure-volume points were fitted
with a linear function and the slope, EES, of this end-systolic
pressure-volume relation and its position at a fixed pressure
level, VES
IND, were used as indices of systolic function. The
fixed pressure level was chosen to fall within the overlap of
actually acquired data (21). Since no single pressure level could
be found applicable to all animals, it was determined in each
animal individually. The mean value for the systolic pressure
level was 12.6 6 2.9 kPa.
2. The dP/dtMAX vs. end-diastolic volume relation (22). For
each beat the maximal rate of pressure rise (dP/dtMAX) was
calculated and plotted vs. end-diastolic volume (VED), which
was defined as the volume at the moment of the R-wave. The
linear relation was characterized by its slope and the value of
dP/dtMAX calculated at a fixed end-diastolic volume, dP/
dtMAX
IND. Like the systolic pressure level, this VED level was
chosen such that, within one dog, actual data points existed at
this level in all conditions. The mean VED level was 15.7 6
2.9 ml.
3. The preload recruitable stroke work relation (PRSW) (23).
The relation between stroke, defined as the area of the
pressure-volume loop, and VED was characterized by its slope
and by the stroke work value at the above-defined VED level,
SWIND.
General hemodynamics. In addition, heart rate, stroke vol-
ume (SV) and cardiac output (CO) were determined. The
latter two were plotted vs. VED and their values at the
above-defined VED level were calculated (SV
IND resp.
COIND).
Statistical analysis. To analyze the effects of dobutamine
we used a multiple linear regression implementation of a
repeated measures analysis of variance with dummy variables
(24). The dummy variables account for the dobutamine level
and the differences between animals. The specific regression
model was: y 5 b0 1 Sbi
AzAi 1 Sbi
DOBzDOBi, where y is the
dependent hemodynamic variable. The n-1 dummy variables
Ai account for between-animal differences, allowing the n
animals to have a different mean value (effects coding). The
DOBi dummy variables code the level of dobutamine stimula-
tion: by using reference cell coding, b0 is the mean value of the
dependent for all animals at baseline and coefficients bi
DOB
quantify the average differences between the various levels of
dobutamine and baseline. Consequently, the mean value of the
dependent at, for example, 10 mg/kg/min is calculated as b0 1
b3
DOB. The standard deviation of the set of animal coefficients
was used as a measure of interanimal variability. F tests were
performed for the model as a whole, for the set of animal
variables and for the set of dobutamine variables. If the F test
for dobutamine revealed significance, we used Dunnett’s test
for multiple comparisons against a single baseline group (24)
to test individual dobutamine levels. The regression model and
subsequent statistical analysis were applied separately to the
control data and the stenosis data. Results are given in Table
1 and are graphically displayed in the Results section. To
further compare the control and stenosis data, t tests were
performed to determine the significance of the difference
between control and stenosis at baseline and at each dobut-
amine level. A p value , 0.05 was considered statistically
significant.
Results
Left circumflex coronary flow. The effects of dobutamine
on QLCX
IND are shown in Figure 1. In control, baseline
QLCX
IND was 25.7 6 2.1 ml/min. Flow started to increase at 10
mg/kg/min and was 45.5 6 4.4 ml/min at 20 mg/kg/min. With
stenosis, baseline flow was reduced by approximately 25%
compared to control, to 19.1 6 3.3 ml/min (p , 0.01). Stenotic
flow did not change significantly with dobutamine. The differ-
ence between control and stenosis was significant at baseline
and at each level of dobutamine.
General hemodynamics. Heart rate. In control, dobut-
amine infusion caused a gradual increase in heart rate from
119 6 2 beats/min at baseline to 185 6 4 beats/min at 20
mg/kg/min. The effects with stenosis were similar, only the
highest dobutamine concentration revealed a significant differ-
ence with control: 169 6 9 beats/min (p , 0.01). (Fig. 2, A).
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Table 1. Effect of Incremental Dobutamine on Various Indices in Control and With Stenosis
Dependent Condition
Model Animals
Baseline b0
Dobutamine
r2 F p IAV F p F p b1
DOB b2
DOB b3
DOB b4
DOB b5
DOB
QLCX
IND (ml/min) Control 0.67 6.68 ** 10.76 6.38 ** 25.67 6 2.11 7.47 ** 21.38 6 3.92 NS 21.12 6 3.39 NS 4.60 6 3.64 NS 10.88 6 3.98 * 19.80 6 3.84 **
Stenosis 0.57 3.17 ** 9.52 5.71 ** 19.09 6 3.27 0.12 NS 22.85 6 5.04 NS 22.87 6 5.04 NS 21.47 6 5.31 NS 23.45 6 5.65 NS 22.05 6 7.06 NS
HR (bpm) Control 0.95 66.44 ** 18.16 38.19 ** 119.42 6 1.72 139.89 ** 5.51 6 3.20 NS 18.38 6 2.77 ** 39.75 6 2.97 ** 59.08 6 3.25 ** 66.01 6 3.13 **
Stenosis 0.86 14.51 ** 13.00 7.51 ** 120.10 6 3.72 22.92 ** 4.84 6 5.74 NS 16.47 6 5.74 * 34.95 6 6.05 ** 55.58 6 6.44 ** 49.18 6 8.04 **
SVIND (ml) Control 0.88 25.14 ** 2.62 32.28 ** 7.26 6 0.26 6.57 ** 0.43 6 0.48 NS 0.78 6 0.41 NS 1.57 6 0.44 ** 1.47 6 0.48 ** 2.34 6 0.47 **
Stenosis 0.85 13.39 ** 3.00 23.22 ** 5.10 6 0.42 1.59 NS 1.01 6 0.65 NS 1.41 6 0.65 NS 1.16 6 0.69 NS 1.75 6 0.73 NS 1.11 6 0.91 NS
COIND (ml/min) Control 0.89 26.86 ** 475 26.37 ** 866 6 54 28.16 ** 90 6 99 NS 256 6 86 ** 561 6 92 ** 740 6 101 ** 976 6 97 **
Stenosis 0.83 11.26 ** 318 13.27 ** 580 6 62 8.84 ** 144 6 96 NS 272 6 96 * 373 6 101 ** 644 6 108 ** 467 6 135 **
VES
IND (ml) Control 0.69 7.29 ** 3.08 5.11 ** 12.12 6 0.68 12.98 ** 23.70 6 1.26 ** 26.20 6 1.09 ** 27.35 6 1.17 ** 26.80 6 1.28 ** 26.32 6 1.24 **
Stenosis 0.64 4.24 ** 4.15 4.01 ** 16.11 6 1.29 4.50 ** 27.66 6 1.98 ** 27.83 6 1.98 ** 25.96 6 2.09 * 25.99 6 2.22 * 25.25 6 2.78 NS
EES (kPa/ml) Control 0.54 3.91 ** 0.68 2.18 * 0.67 6 0.25 8.40 ** 0.69 6 0.47 NS 0.85 6 0.41 NS 1.28 6 0.44 * 2.75 6 0.48 ** 2.04 6 0.46 **
Stenosis 0.72 6.00 ** 0.79 8.71 ** 1.08 6 0.19 2.75 * 0.34 6 0.29 NS 0.35 6 0.29 NS 0.86 6 0.30 NS 0.83 6 0.32 NS 0.96 6 0.40 NS
dP/dtMAX
IND (kPa/s) Control 0.76 10.41 ** 109 3.79 ** 154 6 36 27.62 ** 76 6 66 NS 187 6 57 ** 387 6 62 ** 576 6 67 ** 589 6 65 **
Stenosis 0.75 7.07 ** 86 5.71 ** 138 6 27 8.70 ** 91 6 42 * 168 6 42 ** 189 6 44 ** 259 6 47 ** 222 6 59 **
SdPdT (kPa/s/ml) Control 0.59 4.78 ** 18.58 2.53 ** 3.32 6 6.51 10.62 ** 8.82 6 12.10 NS 16.29 6 10.46 NS 34.79 6 11.24 ** 58.70 6 12.29 ** 73.55 6 11.84 **
Stenosis 0.89 18.71 ** 12.84 16.33 ** 11.82 6 2.20 21.56 ** 4.79 6 3.39 NS 10.20 6 3.39 * 20.23 6 3.57 ** 34.12 6 3.80 ** 25.45 6 4.75 **
SWIND (kPa/ml) Control 0.73 8.96 ** 38.37 7.72 ** 63.87 6 7.66 12.19 ** 15.89 6 14.23 NS 51.34 6 12.30 ** 77.36 6 13.22 ** 76.10 6 14.45 ** 70.02 6 13.93 **
Stenosis 0.71 5.81 ** 48.37 8.33 ** 38.93 6 11.45 2.80 * 41.60 6 17.68 NS 57.07 6 17.68 * 43.56 6 18.61 NS 43.35 6 19.81 NS 9.98 6 24.75 NS
SPRSW (kPa) Control 0.70 7.80 ** 3.95 6.27 ** 6.27 6 0.85 11.79 ** 2.11 6 1.58 NS 4.53 6 1.36 ** 6.96 6 1.46 ** 9.00 6 1.60 ** 9.06 6 1.54 **
Stenosis 0.78 8.48 ** 3.88 7.40 ** 6.35 6 0.86 9.78 ** 2.55 6 1.34 NS 3.90 6 1.34 * 8.44 6 1.41 ** 6.07 6 1.50 ** 8.00 6 1.87 **
The above summarizes the statistical analysis of the effect of dobutamine on the various indices in control and with stenosis. The indices and statistical model are defined and explained in the Methods section. Briefly,
each index (Y) is subjected to a multiple linear regression implementation of a repeated measures analysis of variance, with dummy variables to code the dobutamine level and the animals: Y 5 b0 1 Sbi
A.Ai 1 Sbi
DOB.DOBi.
The first block shows the dependent (Y) and the condition. The second block (Model) gives the coefficient of determination (r2), the F value and the overall significance of the model (* 5 p , 0.05; ** 5 p , 0.01). The
third block (Animals) gives the interanimal variability (IAV), the F for the set of animal variables and the corresponding significance. The next block (Baseline) shows the offset of the regression equation (b0) which corresponds
with the mean value of the dependent at baseline. The Dobutamine block first gives the F value for the set of dobutamine coefficients and the corresponding significance, followed by the individual dobutamine coefficients
(bi
DOB). The dobutamine coefficients quantify the mean difference between the corresponding levels of dobutamine and baseline. SdPdT 5 slope of the dP/dtMAX 2 VED relation; SPRSW 5 slope of the SW 2 VED relation.
NS 5 not significant.
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Stroke volume. In control, SVIND increased gradually from
7.26 6 0.26 ml at baseline to 9.60 5 0.53 ml at maximal
stimulation, the increase being significant at levels from
10 mg/kg/min and higher. With stenosis, the baseline SVIND
was 5.10 6 0.42 ml and slightly increased to 6.52 6 0.78 ml at
5 mg/kg/min dobutamine, but did not increase any further at
higher doses (Fig. 2, B). These increases reached no statistical
significance. The difference between control and stenosis was
significant at baseline and at each level of dobutamine.
Cardiac output. Consequently, control COIND increased
from 866 6 54 ml/min at baseline to 1842 6 111 ml/min at 20
mg/kg/min, whereas with stenosis, COIND was 580 6 62 ml/min
at baseline, reached a peak value of 1224 6 123 ml/min at 15
mg/kg/min and then decreased slightly at maximal stimulation
(Fig. 2, C). Both control and stenosis were increased signifi-
cantly compared to their baseline values at 5 mg/kg/min and
higher. The difference between control and stenosis was always
significant.
Systolic left ventricular function. ESPVR. Without steno-
sis, dobutamine caused a dose-dependent increase in systolic
function evident from a graded leftward shift and steeper slope
of the ESPVR, as shown in a typical example in Figure 3. A
similar effect is shown in Figure 4, A, in which only the
end-systolic points are given. In contrast, Figure 4, B shows the
effects in the presence of a stenosis: First, the baseline ESPVR
relation, that is, without dobutamine stimulation, was shifted
to substantially larger volumes compared to control. Second,
whereas low-dose dobutamine improved systolic function as
evident from a leftward shift of the ESPVR, at 20 mg/kg/min
the relation was similar to baseline. Third, in this example, the
slope of the ESPVR increased gradually with dobutamine, but
was always steeper with stenosis than with control. Figures 5, A
Figure 1. The effects of dobutamine on left circumflex coronary flow
(QLCX
IND) in control (open bars) and with stenosis (shaded bars).
Statistical significance vs. baseline (dobutamine 5 0) within each group
(control or stenosis) is indicated by: # 5 p , 0.05; ## 5 p , 0.01.
Significant differences between control and stenosis at each dobut-
amine level are indicated by: * 5 p , 0.05; ** 5 p , 0.01. Note that
the indexed LCX flow was determined at a fixed end-systolic pressure.
For details see text and Table 1.
Figure 2. The effects of dobutamine
on heart rate (A), stroke volume (B)
and cardiac output (C). Control data
are shown in open bars and stenosis in
shaded bars. Statistical significance vs.
baseline (dobutamine 5 0) within
each group (control or stenosis) is
indicated by: # 5 p , 0.05; ## 5 p ,
0.01. Significant differences between
control and stenosis at each dobut-
amine level are indicated by: * 5 p ,
0.05; ** 5 p , 0.01. Note that the
indexed stroke volume (SVIND) and
cardiac output (COIND) were deter-
mined at a fixed preload (end-
diastolic volume). If the changes in
preload had not been taken into ac-
count, the differences between control
and stenosis would have been less
pronounced. For details see text and
Table 1.
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and B summarizes the findings for the position (VES
IND) and
slope (EES) of the ESPVR. In control, VES
IND gradually
decreases from 12.12 6 0.68 ml at baseline to 4.76 6 1.36 ml
at 10 mg/kg/min; higher dobutamine rates did not shift the
ESPVR further to smaller volumes, but the shift compared to
baseline was significant (p , 0.01) at each level of dobutamine.
With stenosis, the baseline VES
IND was 16.11 6 1.29 ml, which
was significantly higher than the control value. At low dose
dobutamine (2.5 to 5 mg/kg/min), VES
IND decreased, reaching
a minimum of 8.28 6 2.36 ml at 5 mg/kg/min. At higher
dobutamine rates however, VES
IND tended to increase some-
what, reaching a maximum of 10.87 6 3.06 ml at 20 mg/kg/min,
which was no longer significantly different from its value at
baseline. The difference between control and stenosis was
always significant, except at 2.5 mg/kg/min.
In control the slope of the ESPVR, EES, gradually in-
creased from 0.67 6 0.25 kPa/ml at baseline to 3.42 6 0.54
kPa/ml at 15 mg/kg/min. From 10 mg/kg/min onward the values
were significantly increased compared to baseline. With steno-
sis, the value at baseline was 1.08 6 0.19 kPa/ml and increased
to a maximum of 2.04 6 0.44 at 20 mg/kg/min, however the
differences with baseline never reached statistical significance.
The difference between control and stenosis was significant at
baseline (where, interestingly, stenosis was higher; see below)
and at 15 mg/kg/min.
dP/dtMAX 2 VED. Results are shown in Figures 5, C and D.
In control, dP/dtMAX
IND gradually increased from 154 6 36
kPa/s at baseline to 743 6 74 kPa/s at 20 mg/kg/min. From 5
mg/kg/min onward, values were significantly higher than base-
line. With stenosis, the baseline value was 138 6 27 kPa/s and
the maximum was 397 6 54 kPa/s at 15 mg/kg/min. All
dobutamine values were significantly higher than baseline. The
difference between control and stenosis was significant at 10
mg/kg/min and higher levels of dobutamine. In control, the
slope of the dP/dtMAX 2 VED relation increased from 3.3 6
6.5 kPa/s/ml at baseline to 77 6 14 kPa/s/ml at 20 mg/kg/min.
Statistical significance compared to baseline was reached at 10
mg/kg/min and higher levels of dobutamine. With stenosis, the
baseline slope was 11.8 6 2.2 kPa/s/ml and a maximum of
45.9 6 4.4 kPa/s/ml was found at 15 mg/kg/min. The difference
Figure 3. Typical example of pressure-volume loops during control at
four levels of dobutamine. The end-systolic points and the ESPVR are
shown. Note the gradual leftward shift and steeper slope of the
ESPVR with increasing dobutamine.
Figure 4. Typical example of ESPVRs at baseline (circles) and at four
levels of dobutamine in control (A) and with stenosis (B). The dotted
horizontal line indicates the pressure-level at which end-systolic
volume (VES
IND) is determined. The figures illustrate three typical
findings: 1) a substantial rightward shift of end-systolic volumes with
stenosis; 2) in control, dobutamine caused a gradual enhanced systolic
function, evidenced by the leftward shift and steeper slope; with
stenosis, the highest level of dobutamine did not further improve
function but rather its ESPVR almost coincided with the baseline
relation; 3) the slope of the ESPVR with stenosis was not more
shallow, but rather steeper than with control.
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between control and stenosis was significant at baseline where,
like the ESPVR, the stenosis relation was steeper, ad at 15 and
20 mg/kg/min where the control condition was significantly
steeper.
PRSW. Results are shown in Figures 5, E and F. In control,
baseline SWIND was 63.9 6 7.6 kPazml and increased to a
maximum of 141 6 15 kPazml at 10 mg/kg/min. All control
values, except at 2.5 mg/kg/min, were significantly higher than
baseline. With stenosis, baseline SWIND was 49 6 11 kPazml
and the maximum value was 96 6 21 kPazml at 5 mg/kg/min.
The latter was the only one that reached statistical significance
compared to baseline. At all levels, except at 2.5 mg/kg/min,
Figure 5. The effects of dobutamine on position and slope of the
ESPVR, dP/dtMAX 2 VED and PRSW relations, in control (open bars)
and with stenosis (shaded bars). The position of the ESPVR was
characterized by calculating the end-systolic volume intercept at a fixed
systolic pressure, the position of the dP/dtMAX 2 VED and PRSW
relations by calculating the intercept at a fixed end-diastolic volume
(see text for details). A and B show, respectively, the position (VES
IND)
and the slope (EES) of the ESPVR. C and D show the position
(dP/dtMAX
IND) and the slope of the dP/dtMAX 2 VED relation. E and
F show the position (SWIND) and the slope of the PRSW relation.
Statistical significance vs. baseline (dobutamine 5 0) within each group
(control or stenosis) is indicated by: # 5 p , 0.05; ## 5 p , 0.01.
Significant differences between control and stenosis at a each dobut-
amine level are indicated by: * 5 p , 0.05; ** 5 p , 0.01. For details
see text and Table 1.
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control was significantly higher than stenosis. The slope of the
PRSW relation was fairly similar in control and stenosis. In
control, the slope increased from a baseline value of 6.27 6
0.85 kPa to a maximum of 15.3 6 1.8 kPa at 20 mg/kg/min.
Significance compared to baseline was reached starting at
5 mg/kg/min. With stenosis, the baseline slope was 6.35 6
0.86 kPa and the maximum value was 14.8 6 1.7 kPa at 10
mg/kg/min. Values at 5 mg/kg/min and higher were significantly
higher than baseline. The difference between control and
stenosis was only significant at 15 mg/kg/min.
Discussion
Acute coronary occlusion. Several authors have used
pressure-volume analysis to quantify global function in the
presence of acute coronary occlusion. Results in nonejecting
isolated canine hearts (25) and in chronically instrumented
dogs (26) showed a rightward shift of the ESPVR in proportion
to the extent of ischemia, without a significant change in the
slope of the relation. Later on, Kass et al. (27) studied
open-chest dogs and demonstrated both a rightward shift and
a decrease in slope of the ESPVR with coronary occlusion. The
volume shift varied directly with the ischemic bed size, whereas
the decrease in slope was primarily dependent on the baseline
EES. Qualitatively similar results were obtained in humans
during percutaneous transluminal coronary angioplasty (28).
These results could be explained on the basis of a two-
compartment model proposed by Sunagawa et al. (25). This
model contains a noncontracting “ischemic compartment” with
a pressure-volume relation based on the preischemic passive
(diastolic) relation, and a “normal compartment” which re-
tained the original properties. The latter assumption was
recently challenged by Meyer et al. (29). They showed that
end-systolic performance of the nonischemic segment (mea-
sured by its pressure-length relation) is decreased, presumably
due to mechanical interaction with the ischemic segment. This
effect may also party explain the effects on global ESPVR.
Acute coronary stenosis. Whereas with acute occlusion the
active function of the nonperfused myocardium is completely
abolished within minutes (1), the situation in the case of a
stenosis is far more complex. The classical view has been that,
with increasing severity of stenosis, flow is maintained until
vasodilator reserve is completely exhausted. Until the “critical”
stenosis is reached flow and function are not affected, but
beyond that point there is a steep decrease in both. Conse-
quently, “critical stenosis” has been defined as a coronary
constriction sufficient to abolish reactive hyperemia without
altering baseline flow (30). However, several studies indicate
that these two prerequisites are in fact irreconcilable and
abolishment of the hyperemic response requires a reduction of
baseline flow (31–33). Moreover, Canty and Klocke (34)
demonstrated that substantial adenosine-induced vasodilator
reserve persists at coronary pressures as low as 35 mm Hg. In
addition, segmental shortening may be severely impaired de-
spite persistence of transmural vasodilator reserve (35).
Clearly, the classical view is too simple and it has now been
shown that the myocardium may “down-regulate” contractile
function (hibernation [36,37]) in the presence of inadequate
coronary flow reserve to preserve myocardial energy balance
(37–39). Consequently, although the mechanisms are only
party understood (40), myocardium subjected to moderate
ischemia retains some vasodilatory reserve and responsiveness
to adrenoreceptor activation using dobutamine (41,42).
As discussed above, pressure-volume relations, the ESPVR
in particular, have been used to quantify the effects of acute
coronary occlusion, but the effects of critical stenoses have not
been studied with these methods. Previous studies using single-
beat parameters (2,10,11,43,44) generally failed to show signif-
icant changes in global systolic function until flow was substan-
tially reduced.
Effects of stenosis at baseline. The stenosis caused a
reduction in baseline flow of about 25% which implies a
diameter stenosis of more than 80% (45). The present study
shows that the stenosis causes a substantial increase in end-
systolic volume (VES
IND), indicating a reduction in systolic
function, even at baseline (Fig. 5, A). In contrast, the position
of the dP/dtMAX 2 VED relation does not show a difference,
whereas the slopes of ESPVR and dP/dtMAX 2 VED even
suggest a paradoxically enhanced function (Fig. 5, B to D). The
PRSW relation shows that SW (at matched preload) is signif-
icantly reduced, but the slope of this relation is not affected
(Fig. 5, E and F). The reduction in SW is mainly due to a
reduction in SV, as shown by Figure 2, B. Using the SV2 VED
relation, we calculated that maintaining SV in the presence of
a stenosis requires an increase in VED of approximately 5 ml
(likewise, maintaining SW requires an increase in VED of
3.7 ml). This closely matches the 4-ml shift of the ESPVR to
larger volumes (VES
IND went from 12.1 to 16.1 ml). The global
effect of the stenosis at baseline therefore seems to be a shift of
the pressure-volume to a larger volume, thereby maintaining
output through an increased VED (Frank–Starling mecha-
nism), which compensates for the reduction in systolic func-
tion. These findings may explain that at baseline (rest) an effect
on global function in terms of SV, SW or CO is generally not
noticed when changes in preload are not taken into account.
However, the indexed parameters as used in this study, which
are determined at a fixed preload, show substantial effects. In
addition, the slopes of the pressure-volume relations most
frequently used for assessment of systolic function do not
suggest a reduced contractile state with stenosis. In fact, EES
and the slope of dP/dtMAX 2 VED even suggest an enhanced
function. The finding that EES does not decrease with stenosis
is consistent with previous results in the case of coronary
occlusion. Furthermore, the ESPVR and the dP/dtMAX 2 VED
relation were reported to be slightly concave towards the
volume axis (21,46). Therefore, since the loading intervention
generally started from a lower pressure in the presence of a
stenosis, the steeper slopes may partly be artefacts of linear fits
to nonlinear relations. In principle this problem can be avoided
by using a nonlinear fit and calculating the local slope at a fixed
intercept, however, the data ranges obtained during the caval
occlusion were too small to justify reliable nonlinear fits.
As mentioned, only a few studies assessed the effect of a
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coronary stenosis on systolic pressure-volume relations.
Serizawa et al. (47) reduced coronary flow to 50% using clips
on the left circumflex coronary artery (LAD) and the left
anterior descending coronary artery (LCX) in anesthetized
dogs. The ESPVR was not assessed, but left ventricular
pressure was almost unchanged and VES increased by 9 ml.
The volume shift was larger than in our study (65% vs. 33%),
which is likely due to the more severe flow reduction. Similar
to our data, VED was increased such that SV and CO were
almost preserved. The dP/dtMAX was unchanged, however;
taking into account the increase in VED, this would represent
a relative decrease in function. This is in contrast with our
findings where the dP/dtMAX 2 VED relation did not indicate
a reduction in function with stenosis at baseline. This differ-
ence could be related to the more severe flow reduction in
combination with the fact that in Serizawa’s study, both LAD
and LCX were partially occluded, whereas in our study only an
LCX stenosis was applied, in which case a normal region may
compensate for the region supplied by the LCX and collateral
flow may be present.
Effects of dobutamine without stenosis. Dobutamine is
frequently used clinically for short-term inotropic support and
in experimental studies to enhance contractile state and oxygen
demand, however a systematic analysis in terms of pressure-
volume relations using a wide dose range has not been
reported previously. Little et al. (48) studied ESPVRs in
conscious dogs with incremental doses of dobutamine up to 8
mg/kg/min. Several authors studied the effects of inotropic
stimulation on ESPVR, dP/dtMAX 2 VED and PRSW rela-
tions, but generally used only a single level of dobutamine
(20,22,49–53). Our results indicate that in control, dobutamine
gradually increases heart rate and contractile state. Heart rate
continues to rise up to 20 mg/kg/min, the inotropic effect seems
to blunt at 15 mg/kg/min, as evidenced by most of the indices
shown in Figure 5. As a result, the increase in CO at the high
dobutamine levels is mainly due to the increased heart rate.
Interestingly, coronary flow was constant up to 5 mg/kg/min.
Apparently the reduction in cardiac volume as evidenced by
the smaller VES
IND values and, thus, in wall tension counter-
balances the oxygen cost of the inotropic and chronotropic
effects of dobutamine in this range.
Dobutamine and stenosis. The stenosis was such that base-
line flow was reduced by about 25% and dobutamine did not
cause increases in flow. This mimics a situation frequently
encountered in patients in whom a stenosis is fairly well
tolerated at rest, but restricts the ability to respond adequately
in case of increased demands. Whereas in control dobutamine
typically induced a monotonic increase in systolic function
parameters, the response in the presence of a stenosis was
biphasic. At a low dose systolic function improved; in fact, at
2.5 mg/kg/min, systolic function was fully normalized, that is, no
difference with control was present in any index (Fig. 5, A to
F). This may indicate that at low-dose dobutamine the normal
region is able to compensate for the region supplied by the
stenotic artery, or that the stenotic region still has sufficient
inotropic reserve possibly partly supplied by collateral flow.
Systolic function further improved at 5 mg/kg/min, but less than
in control, leading to significant differences between control
and stenosis for VES
IND and SWIND. At doses of 10 mg/kg/min
and higher most indices did not show further improvement in
function, leading to more substantial differences between
control and stenosis. This probably indicates exhaustion of
inotropic reserve in the stenotic region or, given the tendency
for a decrease in function at the highest dobutamine levels,
even the development of wall motion disturbances. In addition,
it has been shown that reduced epicardial coronary flow leads
to an inhomogeneous transmural flow distribution with relative
low flows in the subendocardium. Inotropic and chronotropic
stimulation is likely to enhance this effect (54,55).
It should be noted the main objective in this study was not
so much to detect suspected coronary ischemia, but rather to
quantify the effects of an existing stenosis on global function. In
this context incremental dobutamine was used to simulate
exercise to evaluate the response of the whole ventricle on
increased cardiac oxygen demand. The approach used in the
present study also differs from traditional dobutamine stress
testing as applied in the clinical setting. In contrast to the—
often qualitative—assessment of abnormal wall motion and
regional function, typically using echocardiography, we used
quantitative methods to assess global function. Regional mea-
surements have been shown effective, however, it should be
kept in mind that wall thickening is clearly load-dependent and
may, for example, improve substantially when afterload is
reduced. In contrast, the systolic pressure-volume relations
used in this study have been shown to be relatively load-
independent and therefore, despite the fact that the original
simple concept is disputed (20,21), can be considered to reflect
mainly myocardial properties (18,22,23,49). As an example, the
stenosis generally caused a substantial increase in end-diastolic
volume (preload) which, via the Frank–Starling mechanism,
increases indices such as stroke volume, stroke work and
dP/dtMAX, thereby compensating the changes induced by a
reduced systolic function. However, by comparing the indices
in the various conditions at matched preload, the differences
become apparent. The increased ventricular volume, obviously
accompanied by increases in wall stress, may represent the
initial hallmark of changes in wall structure eventually leading
to remodeling and cardiac failure. Therefore, global systolic
pressure-volume relations may add an important extra dimen-
sion to ventricular function assessment in the presence of a
stenosis.
Conclusions. Dobutamine is a commonly used agent for
short-term inotropic support and has also been used exten-
sively as a pharmacological alternative for physical exercise in
the detection of functionally significant coronary artery steno-
sis. The present study provides an analysis by means of
pressure-volume relations of the effect of dobutamine over a
wide dose range on global systolic function both in control and
in the presence of a critical coronary stenosis. Although data
were obtained in open-chest anesthetized dogs, they may
provide useful information for therapeutic and diagnostic use
of dobutamine in clinical practice.
824 STEENDIJK ET AL. JACC Vol. 32, No. 3
CORONARY STENOSIS AND SYSTOLIC FUNCTION September 1998:816–26
In addition, the present study shows that a coronary stenosis
leading to a 25% decrease in coronary flow induces significant
changes in global systolic function even at baseline. These
effects may not be apparent when function is analyzed with
more traditional single-beat parameters and without taking
into account changes in loading. At baseline, the effect of a
stenosis on systolic function is shown most clearly by a sub-
stantial shift of the ESPVR to a larger volume. More generally,
the results indicate that the positions of systolic pressure-
volume relations provide more consistent and therefore poten-
tially more useful data than the slopes of the relations,
especially with regard to the effect of the stenosis.
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